Tag - Akston Biosciences

Second gen vaccines could hold key to vanquishing virus

The week-long lockdown comes at a time when India is in the midst of a veritable health crisis; not only are many of its ICUs being overwhelmed by an exponential surge in cases of the virus, but the problem is also being compounded by significant vaccine shortages…

Fortunately, there are over 270 novel candidates in development as part of a so-called second generation of vaccines, which could solve the logistical problems posed by the already approved alternatives.

In the Netherlands, for example, Akston […]

AKS-452: The newest vaccine – COVID-19 shot developed by Beverly company reaches trial stage

A COVID-19 vaccine developed by a company in Beverly is being tested on volunteers in the Netherlands. Akston Biosciences announced this week that the first participants in a clinical trial have received doses of its vaccine, called AKS-452. The company is hoping to get approval from European regulators and then seek approval in the United States. Read more >>

Small, local biotechs make progress on their own Covid-19 drugs

The biggest players in the Covid-19 space are the ones that dominate the headlines: Moderna Inc. with its promising new vaccine booster shot candidates, Pfizer and BioNTech with boosters of their own in development and Gilead Sciences, Eli Lilly and Regeneron with antivirals and antibody treatments. But as the pandemic continues around the globe, small Massachusetts firms are developing potential vaccines and treatments of their own — and two of them hit milestones in that process this week. Read […]

Africa’s need for a dedicated Covid-19 vaccine supply

As with so many other facets of global wealth (and health) inequality, the rollout of the four Covid-19 vaccines produced by Western pharmaceutical companies and approved by American and European health officials – the “Big Four” of Pfizer/BioNTech, Moderna, Oxford/AstraZeneca, and Johnson & Johnson – has quickly became yet another tale of haves and have-nots…

Fortunately, a new slate of vaccines fit for use in the least-developed areas of sub-Saharan Africa are currently undergoing trials and could soon offer African […]

Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine candidate. The trial is managed by TRACER Europe B.V., a CRO specializing in fast-track clinical trials; and is being conducted at the University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands. It will test both one- and two-dose regimens, each at three-dose levels. Read more >>

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for AKS-425c, a Once-a-Week Insulin Therapy for Cats

Akston Biosciences, which develops new classes of biologic therapeutics, today announced it has signed licensing, development and supply agreements with Dechra Pharmaceuticals PLC, a global veterinary pharmaceuticals company, for the commercialization of AKS-425c, a once-a-week insulin therapy for the treatment of diabetes in cats. Read more >>

TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452, an innovative anti-COVID-19 vaccine

BEVERLY, Mass., USA & GRONINGEN, the Netherlands, Sept. 01, 2020 Today, TRACER Europe B.V., a Clinical Research Organization (CRO) specializing in fast-track solutions for testing innovative biologic medicines, announced that it will support Akston Biosciences Inc., a leader in the development of novel Fc fusion protein therapeutics, in the Phase 1 clinical testing in the Netherlands of Akston’s lead COVID-19 vaccine candidate, AKS-452. Read more >>